Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2
Terminated
- Conditions
- LeukemiaLymphomaMyelomaMyeloproliferative Diseases
- Interventions
- Drug: FludarabineDrug: MelphalanDrug: AlemtuzumabProcedure: Stem Cell InfusionDrug: TacrolimusDrug: MethotrexateDrug: G-CSFProcedure: Low Dose Donor T-CellsProcedure: High Dose Donor T-Cells
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01518153
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
Phase 1
- Conditions
- Acute LeukemiaMyelodysplastic SyndromeSolid Tumors
- Interventions
- Biological: anti-thymocyte globulinBiological: filgrastimRadiation: Total body irradiationDrug: FludarabineDrug: cyclophosphamideDrug: TacrolimusDrug: Mycophenolate mofetilDrug: Rituximab
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01509300
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 1
Completed
- Conditions
- Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclosporineDrug: Fludarabine PhosphateDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Total-Body IrradiationRadiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
- First Posted Date
- 2012-01-02
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT01503242
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Phase 2
Terminated
- Conditions
- Acute Myelogenous LeukemiaChronic Myelogenous LeukemiaAplastic AnemiaAcute Lymphocytic LeukemiaMyelodysplastic SyndromeChronic Lymphocytic LeukemiaMultiple MyelomaHodgkins DiseaseNon-Hodgkins Lymphoma
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Texas Oncology Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01500161
- Locations
- 🇺🇸
Texas Oncology, Amarillo, Texas, United States
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Phase 2
Terminated
- Conditions
- Metastatic MelanomaSkin Cancer
- Interventions
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT01495572
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Phase 2
Completed
- Conditions
- LeukemiaLymphoma
- Interventions
- Drug: RituximabDrug: 111In IbritumomabProcedure: Planar Scintigraphy ImagingDrug: 90Y IbritumomabTiuxetanDrug: FludarabineDrug: BendamustineDrug: ThymoglobulinDrug: TacrolimusDrug: MethotrexateDrug: MycophenolateDrug: G-CSFProcedure: Stem Cell Transplantation
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01490723
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Phase 1
Withdrawn
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: G-CSFDrug: CytarabineDrug: FludarabineBiological: Donor Natural Killer (NK) cellsBiological: ALT-801
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2014-01-03
- Lead Sponsor
- Altor BioScience
- Registration Number
- NCT01478074
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT01472055
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Daehangno, Jongno-gu, Korea, Republic of
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 3
Completed
- Conditions
- Disorder Related to Bone Marrow TransplantationLeukemiaTransplantation Infection
- Interventions
- Drug: FludarabineDrug: BusulfanDrug: ClofarabineDrug: ThymoglobulinProcedure: Stem Cell InfusionDrug: TacrolimusDrug: Methotrexate
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 256
- Registration Number
- NCT01471444
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Phase 1
Completed
- Conditions
- LymphomaLeukemiaTransplantation, Bone MarrowTransplantation InfectionBlood And Marrow Transplantation
- Interventions
- Drug: FludarabineDrug: MelphalanDrug: Mycophenolate mofetilDrug: TacrolimusProcedure: Cord Blood InfusionDrug: RituximabDrug: ATGDrug: BusulfanDrug: ClofarabineRadiation: Total Body Irradiation (TBI)
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT01471067
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath